Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arno R Bourgonje

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Inflammatory Bowel Diseases|June 16, 2025
Dualistic Implications of Angiotensin-Converting Enzyme 2 (ACE2) Expression in Inflammatory Bowel DiseaseArno R Bourgonje
Gastroenterology|October 24, 2022
Microbial Riboflavin Biosynthesis Associates With Response to Dietary Fiber Consumption: Time to Personalize Adjunct Therapy in Patients With Inflammatory Bowel Disease?Arno R Bourgonje
Journal of Crohn'S & Colitis|August 13, 2022
Evaluating Discriminative Accuracy of Biomarkers in Relation to Binary Study Outcomes: First Validate, Then Celebrate?Arno R Bourgonje
Gastroenterology|February 25, 2026
Rethinking Infliximab Dosing in Acute Severe Ulcerative Colitis with Model-Informed Precision DosingArno R Bourgonje, Paola Mian
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 9, 2025
Advancing Proactive Therapeutic Drug Monitoring with Model-Informed Precision Dosing in Pediatric Crohn's DiseaseArno R Bourgonje, Paola Mian
Digestive Diseases and Sciences|March 6, 2025
Understanding the Impact of Prior Anti-TNF Exposure on Colectomy Risk in Acute Severe Ulcerative ColitisArno R Bourgonje, Maia Kayal
The American Journal of Gastroenterology|November 30, 2023
Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Toward Personalized Evidence-Based Dosing RegimensArno R Bourgonje, Paola Mian
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 15, 2023
The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?Arno R Bourgonje, Antonius T Otten
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBDAntonius T Otten, Arno R Bourgonje, Marijn C Visschedijk
Inflammatory Bowel Diseases|May 17, 2026
Translating multiomics prediction into clinical care in Crohn's disease: Moving beyond proof of conceptFoekjen E Veenstra, Maximilian G Griesbaum, Arno R Bourgonje
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Inflammatory Bowel Diseases|June 16, 2025
Dualistic Implications of Angiotensin-Converting Enzyme 2 (ACE2) Expression in Inflammatory Bowel DiseaseArno R Bourgonje
Gastroenterology|October 24, 2022
Microbial Riboflavin Biosynthesis Associates With Response to Dietary Fiber Consumption: Time to Personalize Adjunct Therapy in Patients With Inflammatory Bowel Disease?Arno R Bourgonje
Journal of Crohn'S & Colitis|August 13, 2022
Evaluating Discriminative Accuracy of Biomarkers in Relation to Binary Study Outcomes: First Validate, Then Celebrate?Arno R Bourgonje
Gastroenterology|February 25, 2026
Rethinking Infliximab Dosing in Acute Severe Ulcerative Colitis with Model-Informed Precision DosingArno R Bourgonje, Paola Mian
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 9, 2025
Advancing Proactive Therapeutic Drug Monitoring with Model-Informed Precision Dosing in Pediatric Crohn's DiseaseArno R Bourgonje, Paola Mian
Digestive Diseases and Sciences|March 6, 2025
Understanding the Impact of Prior Anti-TNF Exposure on Colectomy Risk in Acute Severe Ulcerative ColitisArno R Bourgonje, Maia Kayal
The American Journal of Gastroenterology|November 30, 2023
Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Toward Personalized Evidence-Based Dosing RegimensArno R Bourgonje, Paola Mian
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 15, 2023
The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?Arno R Bourgonje, Antonius T Otten
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBDAntonius T Otten, Arno R Bourgonje, Marijn C Visschedijk
Inflammatory Bowel Diseases|May 17, 2026
Translating multiomics prediction into clinical care in Crohn's disease: Moving beyond proof of conceptFoekjen E Veenstra, Maximilian G Griesbaum, Arno R Bourgonje
Pageof 14